Specialized Healthcare Market Access Consulting | Adjusted EBITDA: €191 TEUR

The company offers specialized consulting services in the areas of market access, health technology assessment (HTA), reimbursement, and market access for pharmaceutical, biotech, and medical technology companies. Its services include the development of market access and reimbursement strategies, the preparation of health economic analyses, the drafting of relevant regulatory and reimbursement documentation, and support throughout the process with public and private payers. In addition, the company supports its clients in successfully positioning new health and medical technologies within national and international healthcare systems.

The company primarily serves B2B clients in the healthcare technology sector, particularly manufacturers and providers of new, already-approved products and solutions. These clients use the consulting services to meet the requirements for public reimbursement or financing of their healthcare technologies. In doing so, clients benefit from specialized support at the intersection of market approval and access to publicly funded healthcare systems.

The market for market access, HTA (Health Technology Assessment), and reimbursement consulting services is benefiting from the increasing complexity of regulatory requirements as well as the growing importance of reimbursement and market access procedures for new therapies, medical devices, and health technologies.

Pharmaceutical, biotechnology, and medical technology companies are increasingly confronted with demanding requirements from regulatory authorities and payers to demonstrate the clinical and economic benefits of new products. At the same time, rising healthcare spending, innovations in specialized therapeutic areas, and stricter regulatory frameworks are driving an increased need for specialized consulting.

The company is positioned in an attractive and growing market segment that benefits from long-term industry trends such as the increasing complexity of HTA, the growth of international pharmaceutical and medical technology markets, and the rising demand for evidence-based reimbursement and market access strategies.

The company competes with specialized market access, HTA (Health Technology Assessment), and reimbursement consulting firms, as well as with larger international healthcare consulting firms, CROs, and healthcare service providers. In addition, many pharmaceutical, biotechnology, and medical technology companies have in-house market access and health economics teams that provide certain services themselves.

The company distinguishes itself through its deep technical expertise in complex market access and reimbursement processes, particularly in challenging therapeutic areas such as rare diseases. The company combines health economics, regulatory, and strategic expertise into an integrated service platform, enabling it to support clients throughout the entire market access process.

Additional competitive advantages include high customer loyalty, a long-standing track record of success, the ability to deliver internationally with projects in numerous countries, and a scalable, asset-light business model. These factors enable the company to maintain a strong position in a highly specialized and growing market segment.